licorice in HIV

The effect of licorice capsule on increasing of CD4 plus T lymphocytes counts in HIV patients treated with antiretroviral therapy without immunological response

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190821044573N1

Enrollment

Registered

2020-01-29

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV. Unspecified human immunodeficiency virus [HIV] disease

Interventions

Intervention 1: Intervention group: Four licorice 500 mg capsules daily 500 mg for three months. Intervention 2: Control group: Four placebo capsules daily for three months.

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: Confirmation of HIV through ELISA test Receiving antiretroviral therapy for at least one year and HIV viral load less than 50 copies per ml and T CD4 plus lymphocyte count less than 200 cells/µL Understand, ability, and willingness to follow study protocols and adhere to its limitations Ability to provide informed written consent to participate in the study Strict adherence to antiretroviral therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CD4+T lymphocytes count. Timepoint: At 4, 8, 12 weeks. Method of measurement: cells/µl.;Interleukin 7 level. Timepoint: At 4, 8, 12 weeks. Method of measurement: pg/µl.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Asadollahi-Amin

Tehran University of Medical Sciences

amiyaneh@gmail.com0098216912811

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026